OncoMed Pharmaceuticals, Inc. (OMED) financial statements (2021 and earlier)

Company profile

Business Address 800 CHESAPEAKE DRIVE
REDWOOD CITY, CA 94063
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:57718088103114130
Cash and cash equivalents1081114131632
Short-term investments48626974909898
Other undisclosed cash, cash equivalents, and short-term investments(0)00(0)000
Assets held-for-sale, not part of disposal group1      
Other undisclosed current assets5222235
Total current assets:64738190105116135
Noncurrent Assets
Property, plant and equipment1233334
Other noncurrent assets1222211
Total noncurrent assets:1445544
TOTAL ASSETS:65778695110120139
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6854757
Accounts payable2311312
Accrued liabilities4543455
Deferred rent credit0   
Restructuring reserve  00000
Deferred revenue and credits28822020
Contract with customer, liability41126 
Other undisclosed current liabilities32334912
Total current liabilities:13213335933440
Noncurrent Liabilities
Liabilities, other than long-term debt4491466148153
Deferred revenue and credits1465148153
Accounts payable and accrued liabilities   0000
Contract with customer, liability  5 
Deferred rent credit444 
Other liabilities0      
Total noncurrent liabilities:4491466148153
Total liabilities:17254249159183193
Stockholders' equity
Stockholders' equity attributable to parent48524446(49)(62)(54)
Common stock0000000
Additional paid in capital410409407405403399397
Accumulated other comprehensive income (loss)(0)(0)(0)0000
Accumulated deficit(362)(357)(363)(359)(452)(461)(451)
Total stockholders' equity:48524446(49)(62)(54)
TOTAL LIABILITIES AND EQUITY:65778695110120139

Income statement (P&L) ($ in millions)

12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
Revenue, net82156
Gross profit:1020782156
Operating expenses(15)(14)(12)(14)(12)(16)(22)
Operating income (loss):(5)6(5)(6)8(11)(15)
Income (loss) from continuing operations before equity method investments, income taxes:(5)6(5)(6)8(11)(15)
Other undisclosed income from continuing operations before income taxes0010000
Income (loss) from continuing operations before income taxes:(5)6(4)(6)8(11)(15)
Income tax expense (benefit)(0) 0(0)1(0)(0)
Net income (loss) available to common stockholders, diluted:(5)6(4)(6)9(11)(15)

Comprehensive Income ($ in millions)

12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
Net income (loss):(5)6(4)(6)9(11)(15)
Comprehensive income (loss):(5)6(4)(6)9(11)(15)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)(0)(0)0(0)0
Comprehensive income (loss), net of tax, attributable to parent:(5)6(4)(6)10(11)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: